Net income for the year ended December 31, 2025, was $447.2 million, a significant increase from $23.4 million in 2024. Total revenue reached $616.3 million in 2025, up from $329.0 million in 2024, primarily driven by BRIUMVI sales. Net product revenue, predominantly from BRIUMVI, increased to $606.9 million in 2025 from $313.7 million in 2024. U.S. net product sales of BRIUMVI were $594.1 million in 2025, compared to $310.0 million in 2024. International sales of BRIUMVI to Neuraxpharm grew to $12.8 million in 2025 from $3.7 million in 2024. The accumulated deficit was significantly reduced to approximately $1.1 billion as of December 31, 2025, from $1.5 billion in 2024. The company completed a $100 million share repurchase program in September 2025, repurchasing 3,502,334 shares at an average price of $28.55 per share. A new $100 million share repurchase program was authorized in September 2025, with no repurchases under it by December 31, 2025. Enrollment commenced in the Phase 3 pivotal program for subcutaneous ublituximab in September 2025, and it was approximately 75% enrolled by February 2026. Enrollment was completed in the randomized cohort of the Phase 3 ENHANCE trial for a consolidated IV BRIUMVI dosing schedule in October 2025. The first patient with progressive multiple sclerosis was dosed with azer-cel in a Phase 1 trial in August 2025. License agreements for TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/anti-CD19) were mutually terminated in September 2025 and April 2025, respectively.